IDP Pharma is a drug discovery company that develops first-in-class medicines (New Chemical Entities) directed to a novel class of therapeutic targets, intrinsically disordered proteins (IDPs). We are currently focused on exploiting new mechanisms of action to treat cancer diseases. Multiple myeloma is one of our priorities.

Our efforts are directed towards promoting a real shift in cancer therapies to improve the lives of patients. To this end, we have built an extraordinary committed team of experts in the field, supported by a professional advisory board, including IDPs and diseases experts, and business professionals.

IDP Pharma was founded in 2015 and the company is located in the Scientific Park of Barcelona (PCB), Spain.

Team

Santiago Esteban, PhD (Chief Executive Officer)

Dr. Esteban got his Ph.D in chemistry at the Institute of Molecular Science (Valencia, Spain). He has worked in several international institutions (KIT, Groningen Institute of Biotechnology, IRB, BSC) and has become an expert in structural biology and computational chemistry in IDPs. In recent years he has gained experience in managing biotech companies.

Laura Nevola, PhD (Chief Scientific Officer)

Dr. Nevola received her degree in medicinal chemistry and Ph.D in Pharmaceutical Science from the University of Rome “Sapienza” (Italy). After her stay at the laboratory of Prof. Dr. Hamilton at Yale University (USA) she moved to the Institute for Research in Biomedicine (IRB Barcelona). She has designed several de novo drugs and led drug discovery projects.

Raúl Insa, MD, PhD, MBA (Chief Development Officer)

CEO and founder of SOM Biotech. Dr. Insa has managed the development of products from discovery to clinical and out-licensing stages. He acummulates more than 30 years of experience in the pharmaceutical sector and he has held senior positions in multinational pharmaceutical companies such as Parke-Davis (Pfizer), UCB Pharma, Uriach Group (Palau Pharma) and ISDIN (Esteve Group).

Jordi Petit Salamó, MBA (Chief Financial Officer)

Mr. Petit (MBA, ESADE) has a broad experience in corporate finance, venture capital and in the financial area of startups, SMEs, multinationals and large companies. He has worked during more than 25 years in different financial directive positions (Betne, Bull Europe, KPMG, Caixa Capital Risc), including biotech companies (Oryzon Genomics).

Advisory board

Evarist Feliu, MD

Prof. Feliu worked in the Department of Hematology of Barcelona Clínic Hospital from 1971 to 1991 under the Direction of Profs. C. Rozman and JL. Vives-Corrons. In 1991 joined the Germans Trias i Pujol Hospital as Head of the Hematology Service in 1991. He has been a center director and scientific director at the Catalan Institute of Oncology (ICO), where he is currently Head of the Hematology Laboratory Service.

Andrew D. Hamilton, PhD

Since 2009, Dr. Andrew D. Hamilton has been the Vice-Chancellor of the University of Oxford. In 2015, New York University announced Andrew Hamilton’s appointment as the 16th President of the University, with his duties starting in January 2016. Previously, he was Provost of Yale University (2004-2008), Professor of Chemistry at the University of Pittsburgh and Assistant Professor of Chemistry at Princeton University. He received his Ph. D in Chemistry from University of Cambridge in 1980. Hamilton’s research has spanned porphyrin, supramolecular, medicinal, bioorganic chemistry and chemical biology.

Miquel Pons, PhD

Prof. Dr. Pons is Professor of Organic Chemistry at the University of Barcelona and Scientific Director of the Laboratory of Nuclear Magnetic Resonance ICTS (The Spanish Singular Facility of NMR). He is part of the boards of the Spanish Biophysical Society and the International Society for Magnetic Resonance. He has pioneered the study of IDPs in Spain and has discovered the regulatory role of the intrinsically disordered Unique domain of c-Src. He has also contributed computational tools for drug discovery.

Gustavo Fuertes Vives, PhD

Dr. Fuertes received his PhD in Nanoscience and Nanotechnology from the University of Valencia and then worked as a postdoctoral fellow at the European Molecular Biology Laboratory (EMBL). Dr. Fuertes is an expert in the biochemistry and biophysics of IDPs and has developed in-vitro technological platforms to study IDPs.